Patents by Inventor Thomas Francis MOORE

Thomas Francis MOORE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSING FOR COMBINATION TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-CD79B ANTIBODY DRUG CONJUGATE
    Publication number: 20220380480
    Abstract: The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.
    Type: Application
    Filed: April 29, 2022
    Publication date: December 1, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Katharina LECHNER, Thomas Francis MOORE, Martin WEISSER, Natalie DIMIER
  • DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY
    Publication number: 20220372156
    Abstract: The present invention relates to methods of treating a B-cell proliferative disorder by administering an anti-CD20/anti-CD3 bispecific antibody, and methods for reduction of adverse effects in response to the administration of the anti-CD20/anti-CD3 bispecific antibody. The present invention further relates to combination treatment methods of treating a B-cell proliferative disorder.
    Type: Application
    Filed: April 29, 2022
    Publication date: November 24, 2022
    Applicants: Hoffmann-La Roche Inc., Roche TCRC Inc.
    Inventors: Katharina LECHNER, Linda LUNDBERG, Thomas Francis MOORE, Peter MORCOS, Martin WEISSER, Marina BACAC, Martin BARRETT, Axel BOEHNKE, David CARLILE, Nassim DJEBLI